1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Drugs In Development, 2022, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 5, 1, 13, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Herpes Zoster (Shingles) - Overview
- Herpes Zoster (Shingles) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Herpes Zoster (Shingles) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
- Herpes Zoster (Shingles) - Drug Profiles
- Herpes Zoster (Shingles) - Dormant Projects
- Herpes Zoster (Shingles) - Discontinued Products
- Herpes Zoster (Shingles) - Product Development Milestones
- Featured News & Press Releases
- May 16, 2022: NanoViricides reports update on Shingles drug
- Jan 07, 2022: Adjuvance Technologies announces issuance of U.S. patent covering semi-synthetic saponin adjuvants
- Mar 30, 2021: Curevo Vaccine announces the approval to conduct a phase 1b clinical trial in South Africa to evaluate safety and immunogenicity of its adjuvanted subunit investigational vaccine, CRV-101, against varicella (Chickenpox) in HIV-positive children
- Sep 15, 2020: Curevo Vaccine announces robust antibody response results of Phase I clinical trial of investigational vaccine for Shingles CRV-101
- May 14, 2020: NanoViricides provides update on drug candidate NV-HHV-101
- Jan 09, 2020: NanoViricides successfully completes required genetic toxicology testing of lead Drug candidate NV-HHV-101
- Jan 07, 2020: NanoViricides has initiated genetic toxicology testing required for an IND for its drug candidate
- Dec 06, 2019: NanoViricides annual meeting of shareholders to be held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT
- Dec 03, 2019: NanoViricides founder Dr. Diwan provides $2,000,000 loan commitment to the company
- Dec 02, 2019: NanoViricides has initiated required safety pharmacology assessment of lead drug candidate towards IND
- Nov 19, 2019: NanoViricides files quarterly report for period ending September 30, 2019 - HerpeCide drug candidate ind enabling studies update, progressing towards clinical trials
- Oct 31, 2019: NanoViricides initiates required dermal sensitization and ocular irritation testing of lead drug candidate towards IND
- Oct 09, 2019: NanoViricides has initiated bio-analytical studies as part of IND-enabling safety and toxicology studies of lead candidate NV-HHV-101
- Oct 03, 2019: NanoViricides is creating nanomedicines to develop antiviral therapies to combat shingles and herpes viruses
- Sep 26, 2019: Curevo Vaccine announces interim results of phase I clinical trial of CRV-101
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Herpes Zoster (Shingles), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Herpes Zoster (Shingles) - Pipeline by Adjuvance Technologies Inc, 2022
- Herpes Zoster (Shingles) - Pipeline by AIM Vaccine Co Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by Amytrx Therapeutics Inc, 2022
- Herpes Zoster (Shingles) - Pipeline by Beijing Green Bamboo Biotechnology Co Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by Beijing Northland Biotech Co Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by BioNTech SE, 2022
- Herpes Zoster (Shingles) - Pipeline by CanSino Biologics Inc, 2022
- Herpes Zoster (Shingles) - Pipeline by CHA Vaccine Institute Co Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by Chengdu Maikekang BioTechnology Co Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by China National Pharmaceutical Group Corp, 2022
- Herpes Zoster (Shingles) - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by CPL Biologicals Pvt Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by Dynavax Technologies Corp, 2022
- Herpes Zoster (Shingles) - Pipeline by EyeGene Inc, 2022
- Herpes Zoster (Shingles) - Pipeline by GC Biopharma Corp, 2022
- Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, 2022
- Herpes Zoster (Shingles) - Pipeline by GreenLight Biosciences Holdings PBC, 2022
- Herpes Zoster (Shingles) - Pipeline by GSK plc, 2022
- Herpes Zoster (Shingles) - Pipeline by Jiangsu Recbio Technology Co Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, 2022
- Herpes Zoster (Shingles) - Pipeline by Shanghai Yidao Biological Technology Co Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by Shulov Innovative Science Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by SK Bioscience Ltd, 2022
- Herpes Zoster (Shingles) - Pipeline by Vaccitech Plc, 2022
- Herpes Zoster (Shingles) - Pipeline by Vapogenix Inc, 2022
- Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, 2022
- Herpes Zoster (Shingles) - Dormant Projects, 2022
- Herpes Zoster (Shingles) - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Herpes Zoster (Shingles), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adjuvance Technologies Inc
- AIM Vaccine Co Ltd
- Amytrx Therapeutics Inc
- Beijing Green Bamboo Biotechnology Co Ltd
- Beijing Northland Biotech Co Ltd
- BioNTech SE
- CanSino Biologics Inc
- CHA Vaccine Institute Co Ltd
- Changchun Bcht Biotechnology Co Ltd
- Chengdu Maikekang BioTechnology Co Ltd
- China National Pharmaceutical Group Corp
- Chongqing Zhifei Biological Products Co Ltd
- CPL Biologicals Pvt Ltd
- DongKoo Bio & Pharma Co Ltd
- Dynavax Technologies Corp
- EyeGene Inc
- GC Biopharma Corp
- GeneOne Life Science Inc
- GreenLight Biosciences Holdings PBC
- GSK plc
- Jiangsu Recbio Technology Co Ltd
- NAL Pharmaceuticals Ltd
- NanoViricides Inc
- Shanghai Yidao Biological Technology Co Ltd
- Shulov Innovative Science Ltd
- SK Bioscience Ltd
- Vaccitech Plc
- Vapogenix Inc
- XBiotech Inc
